United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer and BioNTech have asked European regulators for conditional approval of their experimental coronavirus vaccine — and officials say they could make a decision by the end of the month. The companies said they submitted an application to the European Medicines Agency on Monday for a conditional marketing authorization for their COVID-19 shot, which was.

Pfizer, BioNTech seek COVID-19 vaccine approval in Europe

Pfizer and its German partner BioNTech said Tuesday they have asked the European Union to approve their COVID-19 vaccine, but that distribution is unlikely to start until January. After submitting an application on Monday to the European Medicines Agency (EMA), the drugmakers said the EU regulator accepted the application on Tuesday, per the Wall Street Journal.

Pfizer and BioNTech have asked the EU to approve their vaccine — but first shots might not come until next year

Shares of Pfizer Inc. rallied 2.8% while Germany-based BioNTech SE dropped 2.5% in premarket trading Tuesday, after the company said they submitted their COVID-19 vaccine candidate BNT162b2 for Conditional Marketing Authorization (CMA) to the European Medicines Agency (EMA). If the EMA recommends granting a CMA, that could lead to use of BNT162b2 in Europe before the end of 2020.

Pfizer, BioNTech apply for CMA in Europe for COVID-19 vaccine candidate

Pfizer Inc and BioNTech have applied to the European drugs regulator for conditional authorization of their COVID-19 vaccine, following similar steps in the United States and Britain, the companies said on Tuesday.

Pfizer-BioNTech apply for EU emergency authorization for COVID-19 vaccine

United Continental Hlds

Here's what it means -- and doesn't mean.

This COVID Vaccine Is Already Shipping

Pfizer and BioNTech said they have applied to the European Medicines Agency for the conditional marketing authorization of their coronavirus vaccine.

Pfizer, BioNTech apply for coronavirus vaccine approval in Europe

Pfizer has been working on New Pfizer for almost a decade. The spin offs of Consumer Health and Upjohn appear to be the last steps. Continuation of the policy of dividend growth is a stated priority.

Pfizer: A 'New' Growth Foundation In Genomic Medicine

AbbVie

Autodesk

Cisco Systems

Dominion Energy

Duke Energy

Home Depot

Prudential Financial

Southern Company

AT&T

Unum Group - 6.25% NT REDEEM 15/06/2058 USD 25

Top five holdings add up to 50% of my portfolio. Portfolio currently yields approximately 3.91%.

Eighth Review Of My Dividend Portfolio

The U.K. government has told NHS hospitals to be ready to distribute the COVID-19 vaccine manufactured by Pfizer and BioNTech as soon as next Monday.

This could be the first country to distribute the Pfizer-BioNTech vaccine, as Moderna seeks FDA approval

COVID-19 infections fall 30% across England in second lockdown, study finds.

Pfizer-BioNTech vaccine could be approved ‘within days,' with U.K. set to be first to start COVID-19 shots

Moderna

The U.K. has secured two million more doses of COVID-19 vaccine from Moderna Inc (NASDAQ: MRNA) and is expected to approve the vaccine made by Pfizer Inc (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) this week. What Happened: Moderna is to provide another two million vaccines to the U.K., in addition to a previous 5 million doses, Reuters has reported.

UK To Approve Pfizer-BioNTech Vaccine 'Within Days,' Secures 2M More Doses From Moderna

AstraZeneca

They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.

3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca

Bristol-Myers

Merck

Despite solid gains in pharma sales and profits, Big Pharma's overall share value has pretty much stagnated over the past five years—but better days appear to be ahead, in my opinion.

Berkshire Hathaway Makes Big Bet on Pharma

The company's offering presents challenges at every step from the lab to the syringe.

Pfizer's Vaccine Candidate Is Effective -- But It Has Issues

As drugmaker Pfizer seeks regulatory approval for its COVID-19 vaccine, shipments have already begun making their way to distribution centers via United Airlines charters, according to a Wall Street Journal report.  The Federal Aviation Administration (FAA) approved the shipments, which require the vaccine candidate to be packed in dry ice, according to CNN. 

Pfizer's COVID-19 vaccine is reportedly being flown by United Airlines chartered flights to distribution hubs, in anticipation of FDA approval

United Airlines Holdings Inc. on Friday started operating charter flights to get doses of Pfizer Inc.'s and BioNTech SE's COVID-19 vaccine ready for quick distribution if the vaccine candidate is approved by regulators, according to a Wall Street Journal report that cited people familiar with the matter. Pfizer and BioNTech last Friday submitted an application for the vaccine trial's emergency use authorization, making their vaccine candidate the first in line with U.S. regulators.

United Airlines starts charter flights to distribute Pfizer's COVID-19 vaccine: WSJ

Bank of America

General Motors

Kroger

Liberty Latin America

Snowflake

T-Mobile US

In this article we'll run through the Top 10 Stocks Warren Buffett Just Bought. If you're in a hurry to see the hedge fund legend's highest conviction new stock purchases, you can jump straight to the Top 5 Stocks Warren Buffett Just Bought .

Top 10 Stocks Warren Buffett Just Bought

The company is a proven winner but Pfizer stock won't win any awards for excitement. Long term investors can reap strong dividend rewards; short term movement is murkier.

Pfizer Stock Moved Markets This Month, But Can it Rally?

Is Pfizer (PFE) a great pick from the value investor's perspective right now? Read on to know more.

Should Value Investors Pick Pfizer (PFE) Stock Right Now?

Pfizer's Covid-19 vaccine, made in partnership with BioNTech, needs to be stored at subzero temperatures and distribution challenges lie ahead.

The challenges Pfizer faces distributing its Covid-19 vaccine to the masses

Concho Resources

Devon Energy

Diamondback Energy

Matador Resources

Improving oil prices are definitely a boon for Permian explorers like Devon (DVN), Diamondback (FANG), Concho (CXO) and Matador (MTDR).

Permian Producers in Focus as Crude Price Picks Up

Vaccine news thrust Pfizer center stage this month. But it's PFE stock's beefy dividend that's the real story.

Forget the Vaccine, Buy Pfizer Stock for Its Impressive Cash Flow

Which leading coronavirus vaccine candidate looks best so far?

Here's How the Top 3 Coronavirus Vaccine Candidates Stack Up

The companies might both win the coronavirus vaccine race -- but only one may dominate the market in the long term.

Better Coronavirus Stock: Pfizer or Moderna?

Over six million doses of Pfizer Inc's  (NYSE: PFE) COVID-19 vaccine could be distributed within 24 hours of it being given the go-ahead by the United States Food And Drug Administration, The Washington Post reported Tuesday. What Happened: The vaccine's 6.4 million doses would be sent across communities and the first shots are expected to be given to front-line health-care workers, according to the Post.

News for Pfizer Stock (PFE)